文献速递免疫规划传染病防控与疫情报告

巴西博图卡图大规模疫苗接种活动中Fiocruz ChAdOx COVID-19疫苗的安全性

Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
PubMed 文献 · Vaccine · 2022-08-22

巴西博图卡图于2021年5月16日启动大规模接种,为18-60岁人群间隔12周接种两剂ChadOx1-nCoV19。研究比较首剂和次剂接种前后各六周的急诊和住院记录,共77,683人接种首剂、74,051人接种次剂,疫苗耐受良好,未发现重大安全信号。

要点

  • 两剂接种后1周急诊就诊增加,主要与疫苗非严重副作用(如接种部位疼痛)相关。
  • 鉴定的神经系统特殊不良事件中,多发性硬化3例中有2例为原有疾病复发。
  • 未发现心肌炎、心包炎病例或疫苗相关的血栓栓塞事件增加。

核心结论

  • ChadOx1-nCoV19疫苗在大规模接种中耐受良好,未发现重大安全担忧。

研究设计与样本

  • 研究比较首剂和次剂接种前后各六周的急诊和住院记录,数据来自博图卡图医学院医院,时间为2021年4月4日至9月19日。
  • 首剂和次剂分别于2021年5月和8月接种,两剂间隔12周,接种对象为18-60岁人群。
  • 共77,683人接种首剂,74,051人接种次剂。

主要发现

  • 两剂接种后1周急诊就诊增加,主要见于与疫苗非严重副作用相关的ICD编码,包括接种部位疼痛和其他局部事件。
  • 鉴定的神经系统特殊不良事件中,多发性硬化3例中有2例为原有疾病复发。
  • 一例可能与贝尔麻痹相关的严重住院事件在首剂接种前已发病,该患者同时有中枢神经系统病毒感染。
  • 未发现心肌炎、心包炎病例,也未发现疫苗相关的血栓栓塞事件增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Brazil has been at the core of the COVID-19 pandemic, with the second-highest death toll worldwide. A mass vaccination campaign was initiated on May 16th, 2021, in Botucatu, Brazil, where two doses of ChadOx1-nCoV19 were offered 12 weeks apart to all 18-60- year-olds. This context offers a unique opportunity to study the vaccine safety during a mass campaign. METHODS: The first and second doses of the vaccine were administered in May and August 2021, respectively. Emergency room (ER) and hospitalization records were obtained from the Hospital das Clínicas da Faculdade de Medicina de Botucatu for six weeks before and six weeks after the first and second doses, from 4 April to 19 September 2021. Diagnoses with COVID-19-related ICD codes were excluded to distinguish any trends resulting from the COVID-19 pandemic. ER and hospital visits during the two time periods were compared, including an ICD code comparison, to identify any changes in disease distributions. Data were scanned for a defined list of Adverse Events of Special Interest (AESIs), as presented by the Safety Platform for Emergency Vaccines. RESULTS AND DISCUSSION: A total of 77,683 and 74,051 subjects received dose 1 and dose 2 of ChadOx1-nCoV19, respectively. Vaccination was well tolerated and not associated with any major safety concerns. Increases in ER visits 1 week following both doses were primarily seen in ICD codes related to non-serious side effects of the vaccine, including vaccination site pain and other local events. The neurological AESIs identified (2 of 3 cases of multiple sclerosis) were relapses of a pre-existing condition. One potentially serious hospitalization event for Bell's palsy had onset before vaccination with dose 1, in a patient who also had a viral infection of the central nervous system. There was no myocarditis, pericarditis cases, or vaccine-related increases in thromboembolic events.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Clemens SAC, Fortaleza CMCB, Crowe M, et al. Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil. Vaccine. 2022. PMID: 36055876. doi:10.1016/j.vaccine.2022.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。